76
|
Wu Y, Huang C, Fan Y, Feng J, Pan H, Jiang L, Yang J, Li X, Liu X, Xiong J, Zhao Y, Cheng Y, Ma R, Wang J, Wang Y, Liu Y, Lin D, Shi W, Lin X. JCSE01.09 A Phase II Umbrella Study of Camrelizumab in Different PD-L1 Expression Cohorts in Pre-Treated Advanced/Metastatic Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.267] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
77
|
Ngo N, Elvin J, Vergilio J, Killian J, Lin D, Ross J. P1.14-46 Genomic Profiling of Large Cell Neuroendocrine Carcinomas of Lung: A Path Towards Individualized Treatment Options. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
78
|
Lin D, Yang X. P2.09-14 Evaluation on Inter-Assay Consistency and Inter-Reader Precision for PD-L1 Assays: Ventana SP263 and Dako 22C3 in Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
79
|
Graziano S, Lin D, Elvin J, Vergilio JA, Killian J, Ngo N, Ramkissoon S, Severson E, Hemmerich A, Duncan D, Edgerly C, Ali S, Schrock A, Chung J, Sokol E, Reddy P, McGregor K, Miller V, Alexander B, Ross J. SMARCA4 deficient non-small cell lung cancer (NSCLC): A comprehensive genomic profiling (CGP) study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.105] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
80
|
Quintanilha J, Racioppi A, Wang J, Denning S, Etheridge A, Peña C, Crona D, Lin D, Innocenti F. PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz239.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
81
|
Ou SHI, Sokol E, Trabucco S, Jin D, Frampton G, Graziano S, Elvin J, Vergilio JA, Killian J, Ngo N, Lin D, Ramkissoon S, Severson E, Ali S, Schrock A, Chung J, Reddy P, McGregor K, Alexander B, Ross J. NTRK1-3 genomic fusions in non-small cell lung cancer (NSCLC) determined by comprehensive genomic profiling. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.071] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
82
|
Wu Y, Huang C, Fan Y, Feng J, Pan H, Jiang L, Yang J, Li X, Liu X, Xiong J, Zhao Y, Cheng Y, Ma R, Wang J, Wang Y, Liu Y, Lin D, Shi W, Lin X. P1.01-61 A Phase II Umbrella Study of Camrelizumab in Different PD-L1 Expression Cohorts in Pre-Treated Advanced/Metastatic Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.776] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
83
|
Albanell J, Casadevall D, Sokol E, Albacker L, Elvin J, Vergilio JA, Killian J, Ngo N, Lin D, Ramkissoon S, Severson E, Ali S, Schrock A, Chung J, Reddy P, Miller V, Alexander B, McGregor K, Ross J, Leyland-Jones B. PIK3CA alterations in metastatic breast cancer (mBC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
84
|
Bratslavsky G, Sokol E, Necchi A, Shapiro O, Jacob J, Liu N, Elvin J, Vergilio JA, Killian J, Ngo N, Lin D, Ramkissoon S, Severson E, Ali S, Schrock A, Chung J, Reddy P, Alexander B, Miller V, Ross J. Malignant non-adrenal paraganglioma (mPara) and adrenal pheochromocytoma (mPheo) a comparative comprehensive genomic profiling (CGP) study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
85
|
Imazio M, Klein A, Brucato A, Cremer P, Lewinter M, Abbate A, Lin D, Martini A, Beutler A, Chang S, Crugnale S, Fang F, Gervais A, Perrin R, Paolini JF. P3349RHAPSODY: a pivotal phase 3 trial to assess efficacy and safety of rilonacept, an interleukin 1 alpha and beta blocker, in patients with recurrent pericarditis. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0225] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Recurrent pericarditis (RP) is managed with nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids (CS), and colchicine; up to 15% of pericarditis patients experience multiple recurrences. Interleukin 1 (IL-1) is an important cytokine in the pathophysiology of RP. Rilonacept (KPL-914) is a recombinant fusion protein which binds IL-1α and IL-1β. An ongoing Phase 2 study of rilonacept demonstrated improvements in RP symptoms and inflammation.
Purpose
To evaluate the efficacy and safety of subcutaneous (SC) rilonacept in patients with RP in a Phase 3, randomized, placebo-controlled trial.
Methods
RHAPSODY is a double-blind, placebo-controlled, randomized-withdrawal trial; ∼50 patients will be enrolled (Figure). Patients (≥12 y) must present with at least a third pericarditis episode (all etiologies except infectious and malignant) characterized by a pain score ≥4 on the 11-point Numeric Rating Scale (NRS) and C-reactive protein (CRP) ≥1 mg/dL at screening. Patients may be receiving stable doses of analgesics, NSAIDs, colchicine, and/or CS. After a loading dose (320 mg SC in adults and 4.4 mg/kg SC in children), all patients will receive weekly rilonacept (160 mg SC in adults and 2.2 mg/kg SC in children) during the run-in period. Patients able to taper and discontinue concomitant pericarditis medications and achieve clinical response (mean daily NRS score ≤2.0 during the 7 days before randomization and CRP level ≤0.5 mg/dL) will be randomized 1:1 in a blinded fashion to continued rilonacept or matching placebo weekly SC injections. Investigators may choose different treatments for pericarditis recurrences based on patient clinical status, including bailout rilonacept, while maintaining the blind to prior treatment assignment. The primary efficacy endpoint is time to pericarditis recurrence (adjudicated by an independent committee) in the randomized-withdrawal portion of the study. Secondary efficacy endpoints are the proportion of patients maintaining a clinical response, percentage of days with NRS pain score ≤1, and percentage of patients with no-to-minimal pericarditis symptoms based on patient global assessment. Safety evaluations include adverse events monitoring, physical examinations, and laboratory tests.
Figure 1
Conclusions
RHAPSODY is a pivotal Phase 3 trial evaluating the efficacy and safety of rilonacept in patients with RP using a double-blind, placebo-controlled, randomized-withdrawal design. The results of this study may inform the management of RP.
Acknowledgement/Funding
This study is sponsored by Kiniksa Pharmaceuticals, Ltd.
Collapse
|
86
|
Killian J, Pavlick D, Sokol E, Montesion M, Jin D, Kaplan B, Lin D, Vergilio JA, Elvin J, Ngo N, Severson E, Ramkissoon S, Duncan D, Edgerly C, Hemmerich A, Frampton G, Bratslavsky G, Miller V, Ali S, Ross J. Driving solo? Investigation into collaborating mutations in SDH-deficient neoplasia. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz269.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
87
|
Liu KQ, Wang Y, Zhao Z, Lin D, Zhou CL, Liu BC, Gong XY, Zhao XL, Wei SN, Zhang GJ, Gong BF, Li Y, Liu YT, Mi YC, Wang JX, Wei H. [A single-center, randomized controlled trial of PEG-rhG-CSF and common rhG-CSF to promote neutrophil recovery after induction chemotherapy in newly diagnosed acute myeloid leukemia]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2019; 40:497-501. [PMID: 31340623 PMCID: PMC7342402 DOI: 10.3760/cma.j.issn.0253-2727.2019.06.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
目的 比较初诊急性髓系白血病(AML)患者诱导化疗后骨髓抑制期应用聚乙二醇化重组人G-CSF(PEG-rhG-CSF)与普通重组人G-CSF(rhG-CSF)促进中性粒细胞或白细胞恢复的时间。同时比较两种药物对患者感染发生率、住院时间的影响。 方法 采用前瞻性随机对照研究方法,将2014年8月至2017年12月间符合入组条件的初诊AML患者诱导治疗后按1∶1比例随机分成两组:PEG-rhG-CSF组和rhG-CSF组。对比分析两组患者中性粒细胞计数(ANC)或WBC恢复时间、感染发生率和住院时间。 结果 共入组初诊AML患者60例,PEG-rhG-CSF组30例,rhG-CSF组30例。两组患者除性别构成外,在年龄、化疗方案、化疗前ANC、WBC、诱导化疗疗效方面差异均无统计学意义(P值均>0.05)。PEG-rhG-CSF组患者与rhG-CSF组患者的ANC、WBC恢复中位时间分别为19(14~35)d、19(15~26)d,差异无统计学意义(t=0.580,P=0.566)。PEG-rhG-CSF组、rhG-CSF组患者骨髓抑制期感染的发生率分别为90.0%、93.3%,差异无统计学意义(P=1.000)。两组患者的中位住院时间分别为20.5(17~49)d、21(19~43)d,差异无统计学意义(P=0.530)。 结论 AML患者诱导治疗后应用PEG-rhG-CSF与rhG-CSF无论在ANC或WBC恢复时间,还是在感染的发生率及住院时间均相当。
Collapse
|
88
|
Fang YY, Yamaguchi T, Song SC, Tritsch NX, Lin D. A Hypothalamic Midbrain Pathway Essential for Driving Maternal Behaviors. Neuron 2019; 98:192-207.e10. [PMID: 29621487 DOI: 10.1016/j.neuron.2018.02.019] [Citation(s) in RCA: 123] [Impact Index Per Article: 24.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2017] [Revised: 01/11/2018] [Accepted: 02/21/2018] [Indexed: 01/03/2023]
Abstract
Maternal behaviors are essential for the survival of the young. Previous studies implicated the medial preoptic area (MPOA) as an important region for maternal behaviors, but details of the maternal circuit remain incompletely understood. Here we identify estrogen receptor alpha (Esr1)-expressing cells in the MPOA as key mediators of pup approach and retrieval. Reversible inactivation of MPOAEsr1+ cells impairs those behaviors, whereas optogenetic activation induces immediate pup retrieval. In vivo recordings demonstrate preferential activation of MPOAEsr1+ cells during maternal behaviors and changes in MPOA cell responses across reproductive states. Furthermore, channelrhodopsin-assisted circuit mapping reveals a strong inhibitory projection from MPOAEsr1+ cells to ventral tegmental area (VTA) non-dopaminergic cells. Pathway-specific manipulations reveal that this projection is essential for driving pup approach and retrieval and that VTA dopaminergic cells are reliably activated during those behaviors. Altogether, this study provides new insight into the neural circuit that generates maternal behaviors.
Collapse
|
89
|
Lin D, Zhang L, Mei J, Chen J, Piao Z, Lee G, Dong Y. Mutation of the rice TCM12 gene encoding 2,3-bisphosphoglycerate-independent phosphoglycerate mutase affects chlorophyll synthesis, photosynthesis and chloroplast development at seedling stage at low temperatures. PLANT BIOLOGY (STUTTGART, GERMANY) 2019; 21:585-594. [PMID: 30803106 DOI: 10.1111/plb.12978] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Accepted: 02/19/2019] [Indexed: 06/09/2023]
Abstract
Glycolysis is a central metabolic pathway that provides energy and products of primary metabolites. 2,3-Biphosphoglycerate-independent phosphoglycerate mutase (iPGAM) is a key enzyme that catalyses the reversible interconversion of 3-phosphoglycerate (3-PGA) to 2-phosphoglycerate (2-PGA) in glycolysis. Low temperature is a common abiotic stress in rice production. However, the mechanism for rice iPGAM genes is not fully understood at low temperature. In this study, the rice mutant tcm12, with chlorosis, malformed chloroplasts and impaired photosynthesis, was grown at a low temperature (<20 °C) to the three-leaf stage, while the normal phenotype at 32 °C was used. Chlorophyll fluorescence analysis and transmission electron microscopy were used to examine features of the tcm12 mutant. The inheritance behaviour and function of TCM12 were then analysed thorough map-based cloning, transgenic complementation and subcellular localisation. The thermo-sensitive chlorosis phenotype was caused by a single nucleotide mutation (T→C) on the fifth exon of TCM12 (LOC_Os12g35040) encoding iPGAM, localised to both nucleus and membranes. In addition, TCM12 was constitutively expressed, and its disruption resulted in down-regulation of some genes associated with chlorophyll biosynthesis and photosynthesis at low temperatures (20 °C). This is the first report of the involvement of rice iPGAM gene in chlorophyll synthesis, photosynthesis and chloroplast development, providing new insights into the mechanisms underlying early growth of rice at low temperatures.
Collapse
|
90
|
Lin D, Xu X. [Functional and esthetic reconstruction of a case with tooth wear and temporomandibular joint osteoarthrosis]. ZHONGHUA KOU QIANG YI XUE ZA ZHI = ZHONGHUA KOUQIANG YIXUE ZAZHI = CHINESE JOURNAL OF STOMATOLOGY 2019; 54:399-402. [PMID: 31177679 DOI: 10.3760/cma.j.issn.1002-0098.2019.06.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
|
91
|
Schönenberger K, Reber E, Bally L, Geiser T, Lin D, Stanga Z. P315 Nutritional Assessment in Adults with Cystic Fibrosis (NACYFI study). J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30608-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
92
|
Gabele A, Bevilacqua P, Gfeller M, Hofer M, Eichhorn L, Ettlin S, Lin D. P441 Creating a nationwide hygiene protocol for cystic fibrosis patients in Switzerland. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30733-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
93
|
Henderson CJ, Kapelyukh Y, Scheer N, Rode A, McLaren AW, MacLeod AK, Lin D, Wright J, Stanley LA, Wolf CR. An Extensively Humanized Mouse Model to Predict Pathways of Drug Disposition and Drug/Drug Interactions, and to Facilitate Design of Clinical Trials. Drug Metab Dispos 2019; 47:601-615. [PMID: 30910785 PMCID: PMC6505380 DOI: 10.1124/dmd.119.086397] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2019] [Accepted: 03/04/2019] [Indexed: 02/06/2023] Open
Abstract
Species differences in drug metabolism and disposition can confound the extrapolation of in vivo PK data to man and also profoundly compromise drug efficacy studies owing to differences in pharmacokinetics, in metabolites produced (which are often pharmacologically active), and in differential activation of the transcription factors constitutive androstane receptor (CAR) and pregnane X receptor (PXR), which regulate the expression of such enzymes as P450s and drug transporters. These differences have gained additional importance as a consequence of the use of genetically modified mouse models for drug-efficacy testing and also patient-derived xenografts to predict individual patient responses to anticancer drugs. A number of humanized mouse models for cytochrome P450s, CAR, and PXR have been reported. However, the utility of these models has been compromised by the redundancy in P450 reactions across gene families, whereby the remaining murine P450s can metabolize the compounds being tested. To remove this confounding factor and create a mouse model that more closely reflects human pathways of drug disposition, we substituted 33 murine P450s from the major gene families involved in drug disposition, together with Car and Pxr, for human CAR, PXR, CYP1A1, CYP1A2, CYP2C9, CYP2D6, CYP3A4, and CYP3A7. We also created a mouse line in which 34 P450s were deleted from the mouse genome. Using model compounds and anticancer drugs, we demonstrated how these mouse lines can be applied to predict drug-drug interactions in patients and discuss here their potential application in the more informed design of clinical trials and the personalized treatment of cancer.
Collapse
|
94
|
Feng J, Zhang C, Lischinsky JE, Jing M, Zhou J, Wang H, Zhang Y, Dong A, Wu Z, Wu H, Chen W, Zhang P, Zou J, Hires SA, Zhu JJ, Cui G, Lin D, Du J, Li Y. A Genetically Encoded Fluorescent Sensor for Rapid and Specific In Vivo Detection of Norepinephrine. Neuron 2019; 102:745-761.e8. [PMID: 30922875 PMCID: PMC6533151 DOI: 10.1016/j.neuron.2019.02.037] [Citation(s) in RCA: 294] [Impact Index Per Article: 58.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2018] [Revised: 01/28/2019] [Accepted: 02/21/2019] [Indexed: 12/22/2022]
Abstract
Norepinephrine (NE) is a key biogenic monoamine neurotransmitter involved in a wide range of physiological processes. However, its precise dynamics and regulation remain poorly characterized, in part due to limitations of available techniques for measuring NE in vivo. Here, we developed a family of GPCR activation-based NE (GRABNE) sensors with a 230% peak ΔF/F0 response to NE, good photostability, nanomolar-to-micromolar sensitivities, sub-second kinetics, and high specificity. Viral- or transgenic-mediated expression of GRABNE sensors was able to detect electrical-stimulation-evoked NE release in the locus coeruleus (LC) of mouse brain slices, looming-evoked NE release in the midbrain of live zebrafish, as well as optogenetically and behaviorally triggered NE release in the LC and hypothalamus of freely moving mice. Thus, GRABNE sensors are robust tools for rapid and specific monitoring of in vivo NE transmission in both physiological and pathological processes.
Collapse
|
95
|
Merino D, Weber TS, Serrano A, Vaillant F, Liu K, Pal B, Di Stefano L, Schreuder J, Lin D, Chen Y, Asselin-Labat ML, Schumacher TN, Cameron D, Smyth GK, Papenfuss AT, Lindeman GJ, Visvader JE, Naik SH. Publisher Correction: Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer. Nat Commun 2019; 10:1945. [PMID: 31019194 PMCID: PMC6482144 DOI: 10.1038/s41467-019-09916-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
96
|
Liu KQ, Wei H, Lin D, Wang Y, Zhou CL, Liu BC, Li XL, Zhao Y, Li HJ, Wang CW, Li QH, Li BF, Gong YT, Liu XY, Gong YC, Mi JX, Wang J. [Clinical significance of minimal residual disease in patients with Ph-negative precursor B-acute lymphoblastic leukemia]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2019; 39:724-728. [PMID: 30369181 PMCID: PMC7342254 DOI: 10.3760/cma.j.issn.0253-2727.2018.09.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
目的 探讨微小残留病(MRD)水平在Ph染色体阴性的急性B淋巴细胞白血病(Ph− B-ALL)中的预后意义。 方法 采用多色流式细胞术对2010年9月至2017年11月初诊的193例Ph− B-ALL患者在治疗后1、3、6个月进行骨髓MRD监测,并对不同MRD水平患者的预后进行比较。 结果 中位随访22(1~92)个月,所有193例患者共行497次MRD检测。1个月时MRD水平<0.1%和≥0.1%患者的3年预期无复发生存(RFS)率分别为74.5%和29.9%,3年预期总生存(OS)率分别为67.5%和30.3%;3个月时MRD水平阴性和阳性患者的3年预期RFS率分别为75.6%和29.7%,3年预期OS率分别为71.6%和27.8%;6个月时MRD水平阴性或阳性患者的3年预期RFS率分别为74.6%和11.6%,3年预期OS率分别为74.0%和15.7%,差异均有统计学意义(P值均<0.001)。3个监测点全部达到MRD阴性标准的患者与至少1次未达到MRD阴性标准的患者比较,3年预期RFS、OS率差异均有统计学意义(80.5%对30.5%,77.1%对29.4%,P值均<0.001)。多因素分析结果显示,3个月时的MRD水平是Ph− B-ALL患者独立的预后因素之一。 结论 治疗后MRD监测对Ph− B-ALL的预后判断有重要意义。
Collapse
|
97
|
Kim J, Lee S, Fang YY, Shin A, Park S, Hashikawa K, Bhat S, Kim D, Sohn JW, Lin D, Suh GSB. Rapid, biphasic CRF neuronal responses encode positive and negative valence. Nat Neurosci 2019; 22:576-585. [PMID: 30833699 PMCID: PMC6668342 DOI: 10.1038/s41593-019-0342-2] [Citation(s) in RCA: 80] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2018] [Accepted: 01/18/2019] [Indexed: 12/16/2022]
Abstract
Corticotropin-releasing factor (CRF) that is released from the paraventricular nucleus (PVN) of the hypothalamus is essential for mediating stress response by activating the hypothalamic-pituitary-adrenal (HPA) axis. CRF-releasing PVN neurons receive inputs from multiple brain regions that convey stressful events, but their neuronal dynamics on the timescale of behavior remain unknown. Here, our recordings of PVN CRF neuronal activity in freely behaving mice revealed that CRF neurons are activated immediately by a range of aversive stimuli. By contrast, CRF neuronal activity starts to drop within a second of exposure to appetitive stimuli. Optogenetic activation or inhibition of PVN CRF neurons was sufficient to induce a conditioned place aversion (CPA) or preference (CPP), respectively. Furthermore, CPA or CPP induced by natural stimuli was significantly decreased by manipulating PVN CRF neuronal activity. Together, these findings suggest that the rapid, biphasic responses of PVN CRF neurons encode the positive and negative valences of stimuli.
Collapse
|
98
|
Jiang T, Li W, Lin D, Wang J, Liu F, Ding Z. Imaging features of metanephric adenoma and their pathological correlation. Clin Radiol 2019; 74:408.e9-408.e17. [PMID: 30803811 DOI: 10.1016/j.crad.2019.01.013] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2018] [Accepted: 01/23/2019] [Indexed: 11/17/2022]
Abstract
AIM To analyse the imaging features of metanephric adenoma (MA) and their pathological correlation. MATERIALS AND METHODS The imaging findings in 11 patients with MA were studied retrospectively. Ultrasonography (US), computed tomography (CT), and magnetic resonance imaging (MRI) findings were studied in seven, 11, and six patients, respectively. The enhancement pattern, attenuation, lesion location, size, cystic or solid appearance, capsule sign, and presence of calcifications were evaluated. RESULTS On ultrasonography, MA presented as hypoechoic (4/7), slightly hyperechoic (1/7), isoechoic (2/7), and with a clear boundary. Unenhanced CT showed unclear boundaries (11/11), homogeneous isodensity (8/11), with calcification (1/11), necrosis (1/11), and heterogeneous hyperattenuation (1/11). Mean CT attenuation values on unenhanced and enhanced CT (cortical phase, corticomedullary phase, and excretory phase) were 38.87±6.66, 55.71±17.74, 67.77±16.86, and 65.62±15.99 HU, respectively. The degree of enhancement of the lesions in each phase was statistically significantly lower than that of the surrounding normal renal parenchyma (p=0.00). The pattern of enhancement of the solid component was slight and gradual enhancement (9/11). The tumour was located entirely within the renal medulla in nine cases, and two cases demonstrated an exophytic pattern. All tumours showed a clear boundary on enhanced CT, but capsules were not found. The mean greatest tumour diameter was 3.5 cm. MA showed markedly hyperintense on the diffusion-weighted MRI sequence (DWI) and delayed enhancement of the tumour capsule on enhanced MRI. CONCLUSIONS Imaging features of MA are usually solid and hypovascular, and show prolonged, and homogeneous mild enhancement that is less than that of the surrounding normal renal parenchyma in all phases. MA is markedly hyperintense on DWI.
Collapse
|
99
|
Gu RX, Wei H, Wang Y, Liu BC, Zhou CL, Lin D, Liu KQ, Wei SN, Gong BF, Zhang GJ, Liu YT, Zhao XL, Gong XY, Li Y, Qiu SW, Mi YC, Wang JX. [Impact of duration of antibiotic therapy on the prognosis of patients with acute myeloid leukemia who had Gram-negative bloodstream infection in consolidation chemotherapy]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2019; 39:471-475. [PMID: 30032562 PMCID: PMC7342929 DOI: 10.3760/cma.j.issn.0253-2727.2018.06.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
目的 分析巩固化疗期间伴发革兰阴性菌(G−菌)血流感染的急性髓系白血病(AML)患者抗感染疗程对感染转归的影响。 方法 回顾性分析2010年9月至2016年1月入组“依据危险度分层对急性髓系白血病优化治疗的研究”临床试验的591例AML(非急性早幼粒细胞白血病)患者的血流感染资料,将其中巩固化疗期间发生G−菌血流感染且持续发热时间<7 d的114例次血流感染(89例患者)纳入研究,分析抗感染疗程对感染转归的影响。 结果 114例次血流感染发生时,患者中位ANC为0(0~5.62)×109/L,中性粒细胞缺乏(粒缺)持续的中位时间为9(3~26)d,抗感染治疗的中位时间为7(4~14)d。抗感染疗程≤7 d与>7 d组比较,停药后3 d内再发热比例、再次发生相同菌株血流感染比例分别为1.2%对3.0%、18.5%对21.2%,差异均无统计学意义(P=0.522,OR=0.400,95%CI 0.024~6.591;P=0.741,OR=0.844,95%CI 0.309~2.307)。同时,两组患者均未发生7 d及30 d内感染相关死亡。且倾向性评分平衡患者特征及用药差异因素后,抗感染疗程≤7 d较>7 d组再次发生相同菌株血流感染比例仍无明显增高(P=0.525,OR=0.663,95%CI 0.187~2.352)。 结论 对于巩固化疗期间伴发G−菌血流感染的AML患者,若发热时间<7 d,敏感抗菌药物治疗7 d后停药并不增加停药后3 d内再发热,粒缺期再次出现相同菌株血流感染及感染相关7 d、30 d内死亡风险。提示短疗程抗感染方案可以成为巩固化疗伴发G−菌血流感染AML患者感染控制情况下合理的治疗选择。
Collapse
|
100
|
Tian L, Lin D. [Risk factor analysis of secondary post-tonsillectomy hemorrhage in children]. LIN CHUANG ER BI YAN HOU TOU JING WAI KE ZA ZHI = JOURNAL OF CLINICAL OTORHINOLARYNGOLOGY, HEAD, AND NECK SURGERY 2018; 32:1813-1816. [PMID: 30550216 DOI: 10.13201/j.issn.1001-1781.2018.23.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 09/23/2018] [Indexed: 11/12/2022]
Abstract
Objective: To analyze the risk factors of secondary post-tonsillectomy hemorrhage (PTH) in children, and to provide a theoretical basis for reducing complications after tonsillectomy. Method: A retrospective analysis of 354 children underwent tonsillectomy was performed, among which 42 secondary hemorrhage cases were divided into bleeding group, and other 312 cases were divided into non-bleeding group. To analyze the risk factors of secondary PTH and to discusses the pathogenesis of the hemorrhage, statistical analysis was conducted among eight clinical data including gender, age, reason of surgery, degree of tonsil embedding, surgery approach, surgeon' s skill level, intra-operative hemorrhagic volume, and postoperative absence of upper respiratory tract infection. Result: Univariant analysis showed that there was no statistical difference of gender, reason for operation, surgeon' s skill level, intra-operative hemorrhagic volume and postoperative upper respiratory tract infection different between bleeding group and non-bleeding group, while there was significant statistical difference of age, degree of tonsillar embedding, and surgery approach. Further multivariate logistic regression analysis of the three relevant factors showed that there was a significant correlation between the degree of tonsillar embedding and the surgery approach and the hemorrhage. Conclusion: Hemorrhage after tonsillectomy is a common and potentially fatal complication, with risk factors of the degree of tonsillar embedding, and the surgery approach. .
Collapse
|